Reboxetine augmentation of fluoxetine for patients with major depressive disorder: An 8-week open-label study

被引：0
|
作者：
Rapaport, M
Wilcox, C
Heiser, J
Londborg, P
Schwartz, G
机构：
[1] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
[2] Pharmacol Res Inst, Los Alamitos, CA USA
[3] Summit Res Network, Seattle, WA USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2002年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [1] An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache
    Volpe, Fernando M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (09) : 1449 - +
  • [2] Effect of reboxetine on major depressive disorder in breast cancer patients: An open-label study
    Grassi, L
    Biancosino, B
    Marmai, L
    Righi, R
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (04) : 515 - 520
  • [3] Varenicline Augmentation in Depressed Smokers: An 8-Week, Open-Label Study
    Philip, Noah S.
    Carpenter, Linda L.
    Tyrka, Audrey R.
    Whiteley, Laura B.
    Price, Lawrence H.
    JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (07) : 1026 - 1031
  • [4] An 8-week, open-label study to evaluate the effect of sertraline on the polysomnogram of depressive patients with insomnia
    Bin Zhang
    Yanli Hao
    Xueli Li
    Yanzhen Ren
    Ping Zhou
    Wuhan Liu
    Sleep and Biological Rhythms, 2013, 11 : 165 - 175
  • [5] An 8-week, open-label study to evaluate the effect of sertraline on the polysomnogram of depressive patients with insomnia
    Zhang, Bin
    Hao, Yanli
    Li, Xueli
    Ren, Yanzhen
    Zhou, Ping
    Liu, Wuhan
    SLEEP AND BIOLOGICAL RHYTHMS, 2013, 11 (03) : 165 - 175
  • [6] Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study
    Han, Changsu
    Marks, David M.
    Pae, Chi-Un
    Lee, Bun Hee
    Ko, Young-Hoon
    Masand, Prakash S.
    Patkar, Ashwin A.
    Jung, In-Kwa
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2008, 69 (03): : 221 - 231
  • [7] Effects of Fluoxetine on Fine Motor Performance in Dysthymia: An 8-Week, Nonrandomized, Open-Label Study
    Schrijvers, Didier
    Maas, Yvonne J.
    Sabbe, Bernard G. C.
    CLINICAL THERAPEUTICS, 2009, 31 (01) : 123 - 129
  • [8] Modafinil as augmentation of SSRI monotherapy in major depressive disorder: A 12-week, open-label extension study
    Thase, ME
    Fava, M
    DeBattista, C
    Fannelli, J
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S238 - S238
  • [9] An open label clinical trial of reboxetine in patients with major depressive disorder
    Demir, B
    Soykan, A
    Devrimci-Ozguven, H
    Gögüs, A
    Haller, T
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S221 - S221
  • [10] Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study
    Pae, Chi-Un
    Jeon, Hong Jin
    Lee, Boung Chul
    Seo, Ho-Jun
    Kim, Shin Gyeom
    Park, E-Jin
    Kim, Won
    Kwak, Kyung-Phil
    Han, Changsu
    Cho, Seong-Jin
    Hahn, Sang-Woo
    Jon, Duk-In
    Choi, Jin-Hyuk
    Jun, Tae-Youn
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2013, 28 (06) : 322 - 329
12345